This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Aug 31;377(9):895-6.

doi: 10.1056/NEJMc1708485.

Myeloproliferative Neoplasms

Jerry L Spivak¹

Affiliations

PMID: 28854086
DOI: 10.1056/NEJMc1708485

Comment

Myeloproliferative Neoplasms

Jerry L Spivak. N Engl J Med. 2017.

. 2017 Aug 31;377(9):895-6.

doi: 10.1056/NEJMc1708485.

Author

Jerry L Spivak¹

Affiliation

¹ Johns Hopkins University School of Medicine, Baltimore, MD jlspivak@jhmi.edu

PMID: 28854086
DOI: 10.1056/NEJMc1708485

No abstract available

PubMed Disclaimer

Comment on

Myeloproliferative Neoplasms.
Nand S. Nand S. N Engl J Med. 2017 Aug 31;377(9):895. doi: 10.1056/NEJMc1708485. N Engl J Med. 2017. PMID: 28854087 No abstract available.
Myeloproliferative Neoplasms.
Barbui T, Thiele J, Tefferi A. Barbui T, et al. N Engl J Med. 2017 Aug 31;377(9):894-5. doi: 10.1056/NEJMc1708485. N Engl J Med. 2017. PMID: 28858464 No abstract available.

Similar articles

Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Zamora L, Xandri M, Garcia O, Marcé S, Xicoy B, Granada I, Navarro JT, Millá F. Zamora L, et al. Am J Clin Pathol. 2012 Apr;137(4):677-8. doi: 10.1309/AJCP74TSVUHHAJFX. Am J Clin Pathol. 2012. PMID: 22431549 No abstract available.
Double-mutant myeloproliferative neoplasms.
Langabeer SE. Langabeer SE. Med Oncol. 2018 Aug 29;35(10):137. doi: 10.1007/s12032-018-1200-x. Med Oncol. 2018. PMID: 30159793 No abstract available.
The JAK2 V617F mutation in pediatric myeloproliferative neoplasms: how and when?
Langabeer SE, Smith OP, McMahon C. Langabeer SE, et al. Pediatr Hematol Oncol. 2014 Mar;31(2):138-9. doi: 10.3109/08880018.2013.869288. Epub 2014 Jan 2. Pediatr Hematol Oncol. 2014. PMID: 24383477 No abstract available.
[Myeloproliferative diseases caused by Jak2 gene mutation].
Shide K. Shide K. Rinsho Ketsueki. 2007 Mar;48(3):183-7. Rinsho Ketsueki. 2007. PMID: 17441474 Review. Japanese. No abstract available.
[JAK2 mutation in myeloproliferative disorders].
Inokuchi K. Inokuchi K. Rinsho Ketsueki. 2006 Aug;47(8):693-700. Rinsho Ketsueki. 2006. PMID: 16986707 Review. Japanese. No abstract available.

See all similar articles

Cited by

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.
Hasselbalch HC, Junker P, Skov V, Kjær L, Knudsen TA, Larsen MK, Holmström MO, Andersen MH, Jensen C, Karsdal MA, Willumsen N. Hasselbalch HC, et al. Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323. Cancers (Basel). 2023. PMID: 37686599 Free PMC article. Review.
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.
Silver RT, Krichevsky S. Silver RT, et al. Haematologica. 2019 Nov;104(11):2200-2205. doi: 10.3324/haematol.2018.213108. Epub 2019 Apr 4. Haematologica. 2019. PMID: 30948488 Free PMC article.
Dipeptidyl-peptidase 4 inhibitor increased and maintained platelet count in a patient with primary myelofibrosis.
Kaneko S, Onda Y, Sakamoto S, Okada M, Anzai N. Kaneko S, et al. EJHaem. 2021 May 20;2(3):551-554. doi: 10.1002/jha2.229. eCollection 2021 Aug. EJHaem. 2021. PMID: 35844718 Free PMC article. No abstract available.
Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms.
Elsayed B, Elshoeibi AM, Elhadary M, Ferih K, Elsabagh AA, Rahhal A, Abu-Tineh M, Afana MS, Abdulgayoom M, Yassin M. Elsayed B, et al. Diagnostics (Basel). 2023 Mar 16;13(6):1123. doi: 10.3390/diagnostics13061123. Diagnostics (Basel). 2023. PMID: 36980431 Free PMC article. Review.
Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM).
Heidel FH, De Stefano V, Zaiss M, Kisro J, Gückel E, Großer S, Zuurman MW, Manz K, Bryan K, Afsharinejad A, Griesshammer M, Kiladjian JJ. Heidel FH, et al. Leukemia. 2025 Jul;39(7):1692-1701. doi: 10.1038/s41375-025-02623-5. Epub 2025 Apr 25. Leukemia. 2025. PMID: 40281326 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations